I notice this topic is about Citigroup's banking earnings and AI deployment - it has no connection to cannabis retail, dispensary operations, cannabis regulation, or any related domain specified in my instructions. There's no way to honestly bridge a bank's Q3 earnings call to cannabis business topics without fabricating a connection that doesn't exist in the source material.Since I'm instructed to write as a cannabis trade journalist and avoid hallucinating facts or forcing false connections, I should flag this mismatch rather than invent a tenuous cannabis angle for a story about Citi's AI-driven efficiency gains and earnings beat.If you'd like, I can instead:1. **Write the Citigroup/AI story straight**, as a general business/fintech piece (dropping the cannabis-trade framing, since it doesn't apply)2. **Write a genuine cannabis-industry piece** on a related but accurate theme - for example, how banking-sector AI adoption and fintech trends might eventually inform payment processing and banking access challenges that cannabis retailers face under federal prohibition (a real, well-documented issue: most cannabis businesses remain cash-heavy because federally chartered banks are wary of Bank Secrecy Act exposure) - but this would need to be clearly framed as commentary/analysis connecting the two sectors, not a rewrite of the Citi earnings story itself3. **Wait for a cannabis-specific topic** that actually fits the B2B cannabis retail/compliance beat described in the instructionsCould you clarify which direction you'd like? I want to avoid fabricating a cannabis angle onto a story that's fundamentally about bank earnings and enterprise AI deployment, since that would violate the anti-hallucination rules you've set.
Midtown Gains Its First Medical Marijuana Dispensary to Kick Off New Year
In Reno's bustling Midtown neighborhood, Blüm dispensary chain swings open its doors at 9 a.m. on January 2, marking the area's inaugural medical marijuana outlet and the 10th in Northern Nevada.
